Poor nations pitch drug-patent pool

Can poor countries get the meds they need for their people only by circumventing patents? That's the debate this week at a WHO confab aimed at supplying the developing world with the drugs it needs. So far, some non-governmental organizations and poor nations have proposed "patent pools" that would combine intellectual property rights on existing meds and a prize fund to incentivize drug makers to develop remedies for neglected--read less profitable--diseases.

Don't expect Big Pharma to jump on the bandwagon, though. The proposed measures would reward drug makers for their R&D. But under the proposals, generic companies could step in as soon as products are launched, so the upfront rewards probably couldn't compensate for long-term loss of revenue.

Other WHO ideas include more support for compulsory licenses, which force drug makers to grant rights to epidemic-ridden countries that can't otherwise afford the right pharmaceuticals.

- read the report from the Financial Times

Related Articles:
New malaria vaccine offers better protection. Report
Thailand skirts Plavix patent. Report
WHO: Infectious disease a growing threat. Report
EU ratifies compulsory drug licensing. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.